Skip to content

IQVIA IQV Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Accenture logo
AccentureACN
$1.18B-34.2%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Veeva Systems logo
Veeva SystemsVEEV

Other financials

Income statement

See full
Revenue$4.4B+8.7%
Gross profit$1.4B+8.5%
Operating income$506.0M0.0%
Net income$256.0M-3.8%
EPS (diluted)$1.53-0.6%

Balance sheet

See full
Cash & equivalents$1.9B-6.4%
Total debt$16.2B+3.4%
Total equity$6.2B+6.8%
Total assets$29.9B+4.4%

Cash flow

See full
Operating cash flow$558.0M+26.0%
CapEx$198.0M+31.1%
Free cash flow$360.0M+23.3%

Valuation

See full
Market cap$39.99B+20.9%
Enterprise value$54.32B+16.2%
P/E29.1×+2.3×
P/S2.4×+0.2×

Profitability

See full
Gross margin33%-1.3pp
Operating margin13%-0.9pp
Net margin8.1%+0.2pp
FCF margin12.9%+0.1pp

Returns & leverage

See full
Return on equity23%+3.2pp
Debt / equity2.6×-0.1×
Current ratio0.7×-0.1×

Where this comes from

Reported directly by IQVIA in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: IQVIA’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about IQVIA's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IQVIA's payments for repurchase of common stock?
IQVIA (IQV) reported payments for repurchase of common stock of $398M in Q2 2026.
How has IQVIA's payments for repurchase of common stock changed year-over-year?
IQVIA's payments for repurchase of common stock decreased by 39.4% year-over-year, from $657M to $398M.
What is the long-term trend for IQVIA's payments for repurchase of common stock?
Over 4 years (2021 to 2025), IQVIA's payments for repurchase of common stock has grown at a 32.3% compound annual growth rate (CAGR), from $406M to $1.24B.